Benzinga··NaNovartis Acquires Allergy Biotech Excellergy for Up to $2B in Transformative Deal
Novartis to acquire allergy biotech Excellergy for up to $2 billion, gaining first-in-class ECRI technology and lead candidate Exl-111 currently in Phase 1 trials.
NVSacquisitiondrug development